Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 54

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 54
---
 Annual Reports on Form 10-Kand subsequently filed Quarterly Reports on Form 10-Q,Current Reports on Form 8-Kand other SEC filings, as such filings may be amended from time to time. All of the forward-looking statements made by Clearwater or Enfusion contained or incorporated by reference in this Proxy Statement/Prospectus and all subsequent written and oral forward-looking statements concerning Clearwater, Enfusion, the Transactions or other matters attributable to Clearwater or Enfusion or any person acting on either of their behalf are expressly qualified in their entirety by the cautionary statement above. Readers are cautioned not to place undue reliance on forward-looking statements contained in this Proxy Statement/Prospectus, which speak only as of the date such statements were made. Neither Clearwater nor Enfusion undertakes any obligation to update or revise any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof, even if experience or future changes make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by applicable law. 30

RISK FACTORS

In addition to the other information contained in or incorporated by reference into this Proxy Statement/Prospectus, including, among other things, the matters addressed in the section titled “Cautionary Statement Regarding Forward-Looking Statements,” Enfusion Stockholders should carefully consider the following risks before deciding whether to vote in favor of the Merger Agreement Proposal and the Adjournment Proposal. In addition, Enfusion Stockholders should read and consider the risks associated with each of the businesses of Clearwater and Enfusion because these risks will relate to Clearwater following the completion of the Transactions. Descriptions of some of these risks can be found in Clearwater’s Annual Report on Form 10-Kfor the fiscal year ended December 31, 2023 and Enfusion’s Annual Report on Form 10-Kfor the fiscal year ended December 31, 2023 and, in each case, any amendments thereto, as such risk factors may be updated or supplemented in each company’s subsequently filed Quarterly Reports on Form 10-Qor Current Reports on Form 8-K,which are incorporated by reference into this Proxy Statement/Prospectus. You should also consider the other information in this Proxy Statement/Prospectus and the other documents incorporated by reference into this Proxy Statement/Prospectus. See the section titled “Where You Can Find More Information.”

Risks Relating to the Transactions

Because the market price of Clearwater Common